Rani Therapeutics Holdings (RANI) Operating Expenses (2020 - 2026)

Rani Therapeutics Holdings has reported Operating Expenses for 7 years, with the latest figure at $10.5 million in Q2 2026.

• On a quarterly basis, Operating Expenses changed 0.3% year-over-year to $10.5 million in Q2 2026; TTM through Jun 2026 was $37.8 million, a 25.04% decrease from a year earlier, with the FY2025 full-year figure at $39.9 million, down 26.5% from the prior year.
• Operating Expenses was $10.5 million for Q2 2026 at Rani Therapeutics Holdings, up from $10.0 million in the prior quarter.
• The five-year high for Operating Expenses was $18.3 million in Q2 2023, with the low at $7.3 million in Q3 2025.
• Average Operating Expenses over 5 years is $13.6 million, with a median of $13.6 million recorded in 2022.
• The largest YoY upside for Operating Expenses was 131.44% in 2022 against a maximum downside of 41.18% in 2022.
• Over 5 years, Operating Expenses stood at $17.5 million in 2022, then retreated by 23.16% to $13.4 million in 2023, then rose by 19.0% to $16.0 million in 2024, then slumped by 37.47% to $10.0 million in 2025, then grew by 5.4% to $10.5 million in 2026.
• The last three Operating Expenses figures came in at $10.5 million (Q2 2026), $10.0 million (Q1 2026), and $10.0 million (Q4 2025), per Business Quant data.